drugset / Trial / NCT03373435

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435

Phase 2 Completed 18 enrolled Eiger BioPharmaceuticals
RandomizedCrossoverSingle-blindTreatment

Summary

This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Timeline

Start
2018-03-19
Primary completion
2019-01-30
Completion
2019-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Avexitide Peptide 30 mg Subcutaneous
Subject Avexitide Peptide 60 mg Subcutaneous